Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Covidien plc    COV   IE00B68SQD29

End-of-day quote. End-of-day quote  - 01/26
106.71 USD   -1.26%
08:49aDJAbbott to Acquire St. Jude -- WSJ
04/28DJAbbott Agreed to Buy St. Jude in $25 Billion Deal--6th Update
04/28DJAbbott Agreed to Buy St. Jude in $25 Billion Deal--5th Update
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsSector news 

Covidien plc : Covidien Recalls Duet TRS Staplers on Anatomical Injury Potential

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 03:55pm CEST
   By Saabira Chaudhuri 
 

Covidien PLC (COV) is voluntarily recalling its Duet TRS staplers after receiving one report that links the tissue reinforcement material to a post-operative injury after abdominal surgery.

Launched in 2009, the product is a tissue reinforcement system to support staple lines. To date, Covidien has sold more than 540,000 worldwide.

Covidien on Wednesday said it has stopped manufacturing the units, after concluding that Duet TRS may have the potential to injure adjacent anatomical structures, which may result in life threatening post-operative complications.

The affected product codes range between 4535 to 6048A.

The most recent recall is in addition to one unveiled in January relating to the contraindication of the device in the thoracic cavity. At that time, Covidien received reports of 13 serious injuries and three fatalities following the application of Duet TRS in the thoracic cavity.

On Wednesday, the company said all Duet TRS products can be returned by emailing feedback.customerservice@covidien.com or calling 1-800-722-8772, option 1, to obtain a return goods authorization prior to returning the affected units.

People can report adverse events or quality problems related to the product by calling or emailing the Food and Drug Administration's MedWatch Adverse Event Reporting program.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on COVIDIEN PLC
08:49aDJAbbott to Acquire St. Jude -- WSJ
04/28DJAbbott Agreed to Buy St. Jude in $25 Billion Deal--6th Update
04/28DJAbbott Agreed to Buy St. Jude in $25 Billion Deal--5th Update
04/15DJBusiness Watch -- WSJ
04/14DJSmith & Nephew Holders Oppose Executive Pay Deal
04/06DJMedtronic Says New Inversion Rules Won't Hurt Finances
04/06DJMedtronic Says New Inversion Rules Won't Hurt Finances
03/17DJDrugmaker Mallinckrodt Increases Stock Buyback--Update
03/17DJBiopharmaceutical Company Mallinckrodt Increases Stock Buyback
03/01DJMedtronic Profit Climbs
Advertisement
News chart
Full-screen chart